Axsome Therapeutics Inc Stock
Axsome Therapeutics Inc Stock
Pros and Cons of Axsome Therapeutics Inc in the next few years
Pros
Cons
Performance of Axsome Therapeutics Inc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Axsome Therapeutics Inc | 2.040% | 4.017% | -10.408% | 0.663% | -7.067% | 51.646% | - |
Ardelyx Inc. | 0.130% | -4.466% | -13.831% | 35.956% | 5.848% | -10.686% | - |
Salarius Pharmaceuticals Inc. | 0.950% | -2.778% | -19.231% | -68.421% | -24.324% | -98.250% | -99.994% |
Brainstorm Cell | 1.170% | -0.586% | 0.792% | -81.287% | 119.397% | -80.271% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance at the financial statements of Axsome Therapeutics, a leading player in the Biotechnology & Medical Research industry with the U.S. symbol, there are a few key observations. While the company has experienced an increase in its assets, it has also witnessed a substantial rise in liabilities over the years. Furthermore, Axsome consistently incurs a net loss, which is a cause for concern. However, it is commonly observed that biotech and research-heavy companies often experience significant losses during their early stages of development, owing to the nature of the industry.
Growing Assets: Axsome's total assets have seen consistent growth over the years, increasing from USD 186.1 million in 2020 to USD 331.5 million in 2022. This growth can be considered a positive sign, as it demonstrates the company's capacity to invest in its research and development and expand its operations.
Substantial Cash Reserves: The company has maintained notable cash reserves, totaling to USD 200.8 million by the end of 2022. These reserves can serve as a financial cushion during uncertain times and offer the company the flexibility to capitalize on strategic opportunities.
Comments
News
Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
Investors looking for stocks that can produce heaps of passive income want to look at recent activity from some of the world's most successful investors. Billionaire hedge fund manager Ken Griffin
2 Under-the-Radar Growth Stocks to Consider
Exciting growth stocks are highly coveted, but some fly under the radar for various reasons. And this gives astute investors the opportunity to pounce before their shares rise significantly.
Mid-cap
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
Price matters. That's true whether we're talking about cars, houses, laptops, or anything else -- including stocks.
Three Motley Fool contributors had price in mind when choosing Axsome Therapeutics